Sequenom's Q3 Revenues Nearly Double | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Thursday that its third-quarter revenues jumped 92 percent from the third quarter of 2012, driven by sales of its MaterniT21 Plus test.

The San Diego-based firm brought in total revenues of $44 million for the three months ended Sept. 30, up from $22.9 million for the third quarter of 2012 and up from $34.9 million in the second quarter of 2013. It beat the consensus Wall Street estimate of $40.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.